C92.1
Conditions
Interventions
Group 1: Patients who meet all of the following criteria
1. Adult (male or female) with Philadelphia chromosome positive or BCR::ABL1 -fusion gene positive Chronic myeloid leukemia (CML) in chronic p
= 3rd line TKI has already been chosen by the physician at time of enrollment (first data will be collected at the last visit before change).
4. Change due to warning or failure (adapted from the 20
Sponsors
Ruprecht-Karls-Universität Heidelberg
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Ph+ or BCR::ABL1 -fusion gene positive CML in chronic phase 2. Prior treatment with = 2 TKIs 3. Decision of the treating physician to switch to a TKI approved for third line CML treatment; the TKI has already been selected by the physician at time of enrollment 4. Switch due to "warning" or "failure" (adapted from the 2020 ELN recommendations ) or due to intolerance to the most recent TKI therapy 5. Age = 18 years at the time of change to a new TKI-treatment 6. Signed informed consent prior to participation in this registry
Exclusion criteria
Exclusion criteria: Existing T315I mutation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| no endpoints, initially only collection of data in the register. The analysis of the register data is planned for future projects | — |
Countries
Germany
Outcome results
None listed